GYRE GYRE THERAPEUTICS, INC.

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

GYRE THERAPEUTICS, INC. (GYRE) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full-year 2025 earnings announced March 12, 2026; details in Exhibit 99.1 press release
• Filing covers fiscal year ended December 31, 2025 — annual results, not just a quarterly update

Other GYRE THERAPEUTICS, INC. 8-K Filings

8-K Mar 12, 2026

8-K Mar 2, 2026

Get deeper insights on GYRE THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.